Lucentis ranibizumab: Phase III data

An open-label, U.S. Phase III trial in 305 patients with proliferative diabetic retinopathy showed that 0.5 mg intravitreous Lucentis at baseline and up to every 4 weeks met the primary endpoint of non-inferiority to laser therapy with pan-retinal photocoagulation in the change from baseline in mean visual acuity at 2 years (2.8 vs. 0.2 letters, p<0.001 for non-inferiority). The trial was funded by NIH’s National Eye Institute and conducted by the Diabetic Retinopathy Clinical Research Network. Data were published in the Journal of the American Medical Association and presented at the American Academy of Ophthalmology meeting in Las Vegas. ...